G2GBio Inc

KOSDAQ:456160

G2GBIO, Inc. is a drug delivery system platform company possessing microsphere source technology InnoLAMP for the development of sustained-release pharmaceuticals. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 48 full-time employees. The company went IPO on 2025-08-14. The firm is mainly engaged in the development of long-acting pharmaceutical products, including pipeline candidates such as GB-7001 (for diabetes and obesity) and GB-5001 (for dementia).

मुख्यालय

कोरिया KR

कर्मचारी

48

IPO की तारीख

अग. 14, 2025